Compare IDEXX Laboratories, Inc. (IDXX) vs MACOM Technology (MTSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MACOM Technology — how do they compare? IDEXX Laboratories, Inc. trades at $516.58 (market cap $40.60B), while MACOM Technology trades at $279.44 (market cap $21.32B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and MACOM Technology is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and MACOM Technology for 4 Days on average.
| IDXX | MTSI | |
|---|---|---|
Market Cap | $40.60B | $21.32B |
Volume | 508,758 | 1,504,550 |
Sector | Health | Technology |
52-Week High | $766.68 | $409.68 |
52-Week Low | $504.70 | $122.18 |
Typical Hold Time | 46 Days | 4 Days |
Enterprise Value | $41.50B | $21.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $511.65, up 1.02% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $4.3B in 2025 to $4.6B projected for 2026, with net income margins improving to 24.61%. Recent acquisitions like CoVetAI and product expansions in the UK highlight strategic growth initiatives. Technical indicators show resistance at $515 and support at $509, with moving averages signaling bearish pressure.
Outlook remains positive with a consensus price target of $665 (30% upside), supported by 13 buy ratings. Risks include premium valuation (P/E 35.96) and FX exposure. Earnings beats in recent quarters and raised 2026 EPS guidance reinforce growth trajectory, though insider selling and technical weakness warrant monitoring.
MTSI trades at $275.86, up 4.83% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong Q2 2026 EPS of $1.40 versus $1.35 expected, driven by data center demand growth. Revenue reached $967.26 million in 2025, with a net loss of $54.21 million, but 2026 projections show a profit of $241 million and a 20.69% margin, indicating a significant turnaround.
Outlook is positive with a consensus price target of $401.25, suggesting 45% upside, supported by analyst optimism and AI-driven semiconductor demand. Risks include high valuation multiples, such as a P/E of 88.89, and cash flow volatility, with net cash flow negative in 2025 and 2026. Investors should weigh growth potential against premium pricing and sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MACOM Technology
MACOM develops analog, radio frequency, microwave, and optical semiconductors. Its components are used in telecommunications, data centers, industrial systems, aerospace, and defense applications.
Read more on MTSI →
